Get started
Anavex Life Sciences Corp.Anavex Life Sciences Corp.Anavex Life Sciences Corp.

Anavex Life Sciences Corp.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsForecastSeasonalsETFs

12X1 chart


Full chart

12X1 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪616.90 M‬ CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.450 CHF
Net income (FY)
‪−36.44 M‬ CHF
Revenue (FY)
0.00 CHF
Shares float
‪82.98 M‬
Beta (1Y)
1.31

Employees


Employees (FY)
42
Change (1Y)
+2 +5.00%
Revenue / Employee (1Y)
0.00 CHF
Net income / Employee (1Y)
‪−867.65 K‬ CHF

About Anavex Life Sciences Corp.


Sector
Health Technology
Industry
Biotechnology
CEO
Christopher U. Missling
Website
anavex.com
Headquarters
New York
Founded
2004
ISIN
US0327973006
FIGI
BBG00LVD76F3
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Check out other big names from the same industry as 12X1.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

12X1 news



Ideas



See all ideas 

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs with 12X1 exposure


IWM
iShares Russell 2000 ETF
Weight
0.03%
Market value
‪18.66 M‬
USD
XBI
SPDR S&P BIOTECH ETF
Weight
0.22%
Market value
‪13.33 M‬
USD
IWO
iShares Russell 2000 Growth ETF
Weight
0.05%
Market value
‪6.63 M‬
USD
IBB
iShares Biotechnology ETF
Weight
0.07%
Market value
‪4.49 M‬
USD
VTWO
Vanguard Russell 2000 ETF
Weight
0.03%
Market value
‪3.77 M‬
USD
VHT
Vanguard Health Care ETF
Weight
0.01%
Market value
‪2.51 M‬
USD
IWC
iShares Micro-Cap ETF
Weight
0.18%
Market value
‪1.78 M‬
USD
R2US
SPDR Russell 2000 U.S. Small Cap UCITS ETF
Weight
0.03%
Market value
‪1.26 M‬
USD
VFMO
Vanguard U.S. Momentum Factor ETF
Weight
0.09%
Market value
‪1.14 M‬
USD
LABU
Direxion Daily S&P Biotech Bull 3X Shares
Weight
0.19%
Market value
‪958.60 K‬
USD
ESML
iShares ESG Aware MSCI USA Small-Cap ETF
Weight
0.04%
Market value
‪867.42 K‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of 12X1 is 5.183 CHF — it has increased by 44.49% in the past 24 hours. Watch Anavex Life Sciences Corp. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Anavex Life Sciences Corp. stocks are traded under the ticker 12X1.
We've gathered analysts' opinions on Anavex Life Sciences Corp. future price: according to them, 12X1 price has a max estimate of 40.50 CHF and a min estimate of 13.21 CHF. Watch 12X1 chart and read a more detailed Anavex Life Sciences Corp. stock forecast: see what analysts think of Anavex Life Sciences Corp. and suggest that you do with its stocks.
12X1 reached its all-time high on Jul 5, 2021 with the price of 23.334 CHF, and its all-time low was 3.587 CHF and was reached on Jul 5, 2024. View more price dynamics on 12X1 chart.
See other stocks reaching their highest and lowest prices.
12X1 stock is 30.79% volatile and has beta coefficient of 1.31. Track Anavex Life Sciences Corp. stock price on the chart and check out the list of the most volatile stocks — is Anavex Life Sciences Corp. there?
Today Anavex Life Sciences Corp. has the market capitalization of ‪625.67 M‬, it has increased by 1.11% over the last week.
Yes, you can track Anavex Life Sciences Corp. financials in yearly and quarterly reports right on TradingView.
Anavex Life Sciences Corp. is going to release the next earnings report on Dec 22, 2025. Keep track of upcoming events with our Earnings Calendar.
12X1 earnings for the last quarter are −0.13 CHF per share, whereas the estimation was −0.11 CHF resulting in a −12.41% surprise. The estimated earnings for the next quarter are −0.11 CHF per share. See more details about Anavex Life Sciences Corp. earnings.
Anavex Life Sciences Corp. revenue for the last quarter amounts to 0.00 CHF, matching the estimated figure, and no changes in revenue are expected for the next quarter.
12X1 net income for the last quarter is ‪−10.51 M‬ CHF, while the quarter before that showed ‪−9.91 M‬ CHF of net income which accounts for −6.01% change. Track more Anavex Life Sciences Corp. financial stats to get the full picture.
No, 12X1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 3, 2025, the company has 42 employees. See our rating of the largest employees — is Anavex Life Sciences Corp. on this list?
Like other stocks, 12X1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Anavex Life Sciences Corp. stock right from TradingView charts — choose your broker and connect to your account.